Compare Coursera Inc (COUR) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs DexCom, Inc. — how do they compare? Coursera Inc trades at $5.16 (market cap $1.39B), while DexCom, Inc. trades at $84.11 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 22.9× Coursera Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and DexCom, Inc. for 62 Days on average.
| COUR | DXCM | |
|---|---|---|
Market Cap | $1.39B | $31.86B |
Volume | 9,728,980 | 3,607,070 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $92.34 |
52-Week Low | $4.64 | $54.84 |
Typical Hold Time | 47 Days | 62 Days |
Enterprise Value | $648.49M | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COUR trades at $5.27, up 3.13% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Revenue growth is solid, rising from $524M in 2022 to $758M in 2025, yet the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights AI platform developments and institutional interest, including large call option purchases and a new stake by Deutsche Bank AG.
The outlook is cautiously optimistic, driven by revenue growth and analyst consensus favoring a buy with a $7.40 price target. However, persistent losses, integration risks from acquisitions, and competitive pressures in edtech pose significant risks. Upside depends on converting subscriber growth into profitability.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
